When tested against 312 clinical isolates of rapidly growing mycobacteria, the quinolone pipemidic acid correctly separated Mycobacterium chelonae (M. chelonei) from Mycobacterium fortuitum biovar fortuitum but not from biovarperegrinum or the third biovar complex. The new 4-quinolone ciprofloxacin correctly separated all three biovars of M. fortuitum from M. chelonae and appears to provide a better taxonomic test.
The observation that there are major differences in antimicrobial susceptibility between the two pathogenic species of rapidly growing mycobacteria, Mycobacterium fortuitum and Mycobacterium chelonae (formerly M. chelonei) (8, 9) , has stimulated greater interest in the separation of the two species in the clinical laboratory. The best-known biochemical tests which differentiate these two species are those of nitrate reduction and iron uptake (4, 7) . M. fortuitum gives a positive reaction to both tests, but M. chelonae gives a negative reaction. More recently, disk diffusion susceptibility to polymyxin B and pipemidic acid on Mueller-Hinton agar has also been used. Polymyxin B is a basic peptide antibiotic, and pipemidic acid is a quinolone antibiotic related to nalidixic acid. Several studies of M. fortuitum have shown this species to give zones of inhibition of .10 mm to polymyxin B, whereas isolates of the two subspecies of M. chelonae give no zones of inhibition (11, 12 ). Casal and Rodriguez tested 37 strains of M. fortuitum and found all to be susceptible to pipemidic acid, whereas the 11 strains of M. chelonae were resistant. These isolates were identified to the species level only (1, 2) . Recently, we noted that not all strains belonging to M. fortuitum are susceptible to pipemidic acid, and this difference is related to the biovar group to which the isolate belongs. This difference was not noted, however, with the new related quinolone, ciprofloxacin.
Clinical strains of M. fortuitum (n = 162) and M. chelonae (n = 150), referred for susceptibility testing between 1979 and 1985, were studied. Identification was performed by the Mycobacteriology Reference Section of the Centers for Disease Control by standard methods (6) . Of the 162 isolates of M. fortuitum, 120 belonged to biovar fortuitum, 9 were biovar peregrinum, and 33 belonged to the unnamed third biovar complex (6 (1, 2, 5). In the study by Casal and Rodriguez, the isolates were not identified to the biovar level, so it is not possible to determine whether isolates from biovars other than fortuitum were present (1). Lévy-Frébault et al. (5) identified nine isolates of biovar fortuitum, eight isolates of biovar peregrinum, and two isolates of the third biovar complex (according to our classification scheme) and found all to be susceptible to pipemidic acid. The type strains of biovarfortuitum (ATCC 6841) and biovar peregrinum (ATCC 14467) were reported as susceptible, a finding confirmed by our study. The reason for the differences in the other isolates of biovar peregrinum and the third biovar complex is not known. Most of their isolates other than the type strains were environmental (six of nine), compared with our study, in which no environmental isolates were studied, and the geographic sources (France and the southwestern United States) were different, factors which may be important.
Although all clinical isolates of M. chelonae and the type strain of subsp. abscessus (ATCC 19977) were resistant to ciprofloxacin, the type strain of subsp. chelonae (ATCC 35752) was susceptible. This strain was also tested by the Lévy-Frébault group (as NCTC 946) (5) with the same results. This strain is a laboratory strain that has been passaged multiple times over many years.
In a recent study of 76 disease-producing isolates of M. fortuitum from the southwestern United States, 17% belonged to the third biovar complex and 4% belonged to biovar peregrinum (10) . Based on the prevalence of these biovars in human disease and the frequency with which they are resistant to pipemidic acid (88%), this test cannot be used in the Southwest to differentiate between M. fortuitum and M. chelonae with an acceptable degree of accuracy.
In contrast to pipemidic acid, ciprofloxacin was uniformly successful in differentiating these two species, although fewer strains were tested. Collins et al. (3) We acknowledge the help and encouragement of Vella Silcox, Chief of the Mycobacterial Reference Section of the Centers for Disease Control, Atlanta, Ga., who identified all of these isolates.
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